Literature DB >> 6941455

In vitro susceptibility of anaerobic bacteria to nitroimidazoles.

B Olsson-Liljequist, C E Nord.   

Abstract

The in vitro susceptibility of 355 Swedish clinical isolates of anaerobic bacteria to three nitroimidazole drugs was determined by the agar dilution method. The drugs were metronidazole, tinidazole and ornidazole. In addition the in vitro susceptibility of 32 strains of clostridium difficile to metronidazole was determined. Gram-negative rods and clostridia were inhibited by 4 microgram/ml or less of all three compounds except one strain of C. difficile, which was not inhibited by 16 microgram/ml of metronidazole. Against strains of the Bacteroides fragilis group, tinidazole was slightly more active than metronidazole and ornidazole. Only about 70% of anaerobic cocci (peptococci and peptostreptococci) were inhibited by 4 microgram/ml of the three drugs, whereas the remaining isolates were resistant (minimum inhibitory concentration greater than or equal to 8 microgram/ml). Anaerobic streptococci were not included in this material. Actinomyces, arachnia and propionibacteria were resistant to the nitroimidazole drugs. At achievable serum levels, nitroimidazoles inhibited the majority of anaerobic bacteria found with greatest frequency in anaerobic infections.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6941455

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  9 in total

1.  In vitro activity of cefoperazone plus sulbactam compared with that of other antimicrobial agents against anaerobic bacteria.

Authors:  H M Wexler; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

Review 2.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

Review 3.  Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection.

Authors:  Fawziah Marra; Karen Ng
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

4.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 5.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

Review 7.  Tinidazole in anaerobic infections: a review of its antibacterial activity, pharmacological properties and therapeutic efficacy.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-08       Impact factor: 9.546

Review 8.  Tinidazole--microbiology, pharmacology and efficacy in anaerobic infections.

Authors:  C E Nord; L Kager
Journal:  Infection       Date:  1983 Jan-Feb       Impact factor: 3.553

9.  Metronidazole resistance in Clostridium difficile is heterogeneous.

Authors:  T Peláez; E Cercenado; L Alcalá; M Marín; A Martín-López; J Martínez-Alarcón; P Catalán; M Sánchez-Somolinos; E Bouza
Journal:  J Clin Microbiol       Date:  2008-07-23       Impact factor: 5.948

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.